Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To analyze the impact of radical cytoreductive surgery—as part of primary tumor debulking—on the amount of residual tumor and survival in patients with advanced ovarian cancer and to evaluate the prognostic significance of no gross residual disease (RD) after surgery.
Medical records of 203 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC–IV ovarian cancer were reviewed. All patients underwent primary cytoreductive surgery followed by taxane- and platinum-based chemotherapy. Various clinicopathologic characteristics were collected.
Of 203 patients, 119 patients underwent simple surgery, while radical surgery was performed in 84 patients. Advanced age (hazard ratio [HR] 1.04, 95 % confidence interval [CI] 1.02–1.06, P < 0.01), FIGO stage IV disease (HR 3.61, 95 % CI 1.48–8.83, P < 0.01), and grossly visible RD (HR 3.24, 95 % CI 1.90–5.53, P < 0.01) were identified as significant factors associated with poor prognosis in the entire cohort of 203 patients. Radical surgery (HR 0.56, 95 % CI 0.37–0.87, P = 0.01) was associated with improved survival. In the subgroup of patients with stage IIIC disease with peritoneal carcinomatosis, independent prognostic factors were advanced age (HR 1.04, 95 % CI 1.01–1.06, P = 0.01), radical surgery (HR 0.58, 95 % CI 0.35–0.96, P = 0.03), and grossly visible RD (HR 2.86, 95 % CI 1.55–5.30, P < 0.01). Patients with no gross RD had the longest overall survival (86 months) compared with RD 0.1–1 cm (46 months) and RD >1.0 cm (37 months) (P < 0.01).
No gross RD is associated with improved overall survival, and radical surgery was effective for achieving no gross RD.
- Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin. 61: pp. 69-90 CrossRef
- Shih, KK, Chi, DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 21: pp. 75-80 CrossRef
- Hoskins, WJ, McGuire, WP, Brady, MF (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 170: pp. 974-979
- Bristow, RE, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20: pp. 1248-1259 CrossRef
- Bristow, RE, Carmen, MG, Kaufman, HS, Montz, FJ (2003) Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg. 197: pp. 565-574 CrossRef
- Park, JY, Seo, SS, Kang, S, Lee, KB, Lim, SY, Choi, HS, Park, SY (2006) The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 103: pp. 977-984 CrossRef
- Aletti, GD, Podratz, KC, Jones, MB, Cliby, WA (2006) Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 203: pp. 521-526 CrossRef
- Eisenhauer, EL, Abu-Rustum, NR, Sonoda, Y (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol Oncol. 103: pp. 1083-1090 CrossRef
- Salani, R, Zahurak, ML, Santillan, A, Giuntoli, RL, Bristow, RE (2007) Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 107: pp. 495-499 CrossRef
- Bristow, RE, Peiretti, M, Zanagnolo, V, Salani, R, Giuntoli, RL, Maggioni, A (2008) Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol. 109: pp. 364-369 CrossRef
- Chi, DS, Eisenhauer, EL, Zivanovic, O (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 114: pp. 26-31 CrossRef
- Kommoss, S, Rochon, J, Harter, P (2010) Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol. 17: pp. 279-286 CrossRef
- Peiretti, M, Zanagnolo, V, Aletti, GD (2010) Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 119: pp. 259-264
- Omura, GA, Brady, MF, Homesley, HD (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 9: pp. 1138-1150
- Eisenkop, SM, Friedman, RL, Wang, HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 69: pp. 103-108 CrossRef
- Chi, DS, Eisenhauer, EL, Lang, J (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol. 103: pp. 559-564 CrossRef
- Aletti, GD, Dowdy, SC, Gostout, BS (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 107: pp. 77-85 CrossRef
- Winter, WE, Maxwell, GL, Tian, C (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 25: pp. 3621-3627 CrossRef
- Winter, WE, Maxwell, GL, Tian, C (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 26: pp. 83-89 CrossRef
- Bois, A, Reuss, A, Pujade-Lauraine, E, Harter, P, Ray-Coquard, I, Pfisterer, J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 115: pp. 1234-1244 CrossRef
- Wimberger, P, Wehling, M, Lehmann, N (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol. 17: pp. 1642-1648 CrossRef
- Eisenkop, SM, Spirtos, NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?. Gynecol Oncol. 82: pp. 489-497 CrossRef
- Covens, AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 78: pp. 269-274 CrossRef
- Berman, ML (2003) Future directions in the surgical management of ovarian cancer. Gynecol Oncol. 90: pp. S33-S39 CrossRef
- Crawford, SC, Vasey, PA, Paul, J, Hay, A, Davis, JA, Kaye, SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol. 23: pp. 8802-8811 CrossRef
- Chang, SJ, Bristow, RE (2012) Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining “optimal” residual disease. Gynecol Oncol. 125: pp. 483-492 CrossRef
- Griffiths, CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 42: pp. 101-104
- Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(8):CD007565.
- Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(4):CD007697.
- Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer
Annals of Surgical Oncology
Volume 19, Issue 13 , pp 4059-4067
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea
- 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine School of Medicine, Orange, CA, USA